| Multiple associated proteins regulate proteasome structure and function DS Leggett, J Hanna, A Borodovsky, B Crosas, M Schmidt, RT Baker, ... Molecular cell 10 (3), 495-507, 2002 | 780 | 2002 |
| Proteasome subunit Rpn1 binds ubiquitin-like protein domains S Elsasser, RR Gali, M Schwickart, CN Larsen, DS Leggett, B Müller, ... Nature cell biology 4 (9), 725-730, 2002 | 587 | 2002 |
| The axial channel of the proteasome core particle is gated by the Rpt2 ATPase and controls both substrate entry and product release A Köhler, P Cascio, DS Leggett, KM Woo, AL Goldberg, D Finley Molecular cell 7 (6), 1143-1152, 2001 | 556 | 2001 |
| Suppression of cancer relapse and metastasis by inhibiting cancer stemness Y Li, HA Rogoff, S Keates, Y Gao, S Murikipudi, K Mikule, D Leggett, W Li, ... Proceedings of the National Academy of Sciences 112 (6), 1839-1844, 2015 | 508 | 2015 |
| Deubiquitinating enzyme Ubp6 functions noncatalytically to delay proteasomal degradation J Hanna, NA Hathaway, Y Tone, B Crosas, S Elsasser, DS Kirkpatrick, ... Cell 127 (1), 99-111, 2006 | 450 | 2006 |
| ARQ 197, a novel and selective inhibitor of the human c-Met receptor tyrosine kinase with antitumor activity N Munshi, S Jeay, Y Li, CR Chen, DS France, MA Ashwell, J Hill, ... Molecular cancer therapeutics 9 (6), 1544-1553, 2010 | 383 | 2010 |
| Ubiquitin chains are remodeled at the proteasome by opposing ubiquitin ligase and deubiquitinating activities B Crosas, J Hanna, DS Kirkpatrick, DP Zhang, Y Tone, NA Hathaway, ... Cell 127 (7), 1401-1413, 2006 | 378 | 2006 |
| Ubiquitin depletion as a key mediator of toxicity by translational inhibitors J Hanna, DS Leggett, D Finley Molecular and cellular biology 23 (24), 9251-9261, 2003 | 274 | 2003 |
| Purification of proteasomes, proteasome subcomplexes, and proteasome-associated proteins from budding yeast DS Leggett, MH Glickman, D Finley Ubiquitin-Proteasome Protocols, 57-70, 2005 | 123 | 2005 |
| STAT3 pathway inhibitors and cancer stem cell inhibitors Z Jiang, CJ Li, W Li, D Leggett US Patent 8,877,803, 2014 | 32 | 2014 |
| A dose-escalation phase I study of a first-in-class cancer stemness inhibitor in patients with advanced malignancies. A Langleben, JG Supko, SJ Hotte, G Batist, HW Hirte, H Rogoff, Y Li, W Li, ... Journal of Clinical Oncology 31 (15_suppl), 2542-2542, 2013 | 29 | 2013 |
| A phase I extension study of BBI608, a first-in-class cancer stem cell (CSC) inhibitor, in patients with advanced solid tumors. DJ Jonker, J Stephenson, WJ Edenfield, JG Supko, Y Li, W Li, M Hitron, ... Journal of Clinical Oncology 32 (15_suppl), 2546-2546, 2014 | 27 | 2014 |
| A phase 1b study of the cancer stem cell inhibitor BBI608 administered with paclitaxel in patients with advanced malignancies. M Hitron, J Stephenson, KN Chi, WJ Edenfield, D Leggett, Y Li, W Li, ... Journal of Clinical Oncology 32 (15_suppl), 2530-2530, 2014 | 24 | 2014 |
| ARQ 197, a highly selective small molecule inhibitor of c-Met, with selective antitumor properties in a broad spectrum of human cancer cells S Jeay, N Munshi, J Hill, M Moussa, M Ashwell, D Leggett, C Li Cancer Research 67 (9_Supplement), 2369-2369, 2007 | 24 | 2007 |
| High-content fluorescent-based assay for screening activators of DNA damage checkpoint pathways B Zhang, X Gu, U Uppalapati, MA Ashwell, DS Leggett, CJ Li Journal of biomolecular screening 13 (6), 538-543, 2008 | 18 | 2008 |
| Biochemical characterization of Caenorhabditis elegans UBC-1: self-association and auto-ubiquitination of a RAD6-like ubiquitin-conjugating enzyme in vitro SD LEGGETT, MEP CANDIDO Biochemical Journal 327 (2), 357-361, 1997 | 18 | 1997 |
| Caenorhabditis elegans UBC-1, a Ubiquitin-Conjugating Enzyme Homologous to Yeast RAD6/UBC2, Contains a Novel Carboxy-Terminal Extension That Is … DS LEGGETT, D JONES, EPM CANDIDO DNA and cell biology 14 (10), 883-891, 1995 | 16 | 1995 |
| Compounds and compositions for targeting cancer stem cells CJ Li, D Leggett, Y Li, W Li US Patent 9,084,766, 2015 | 11 | 2015 |
| Broad spectrum anti-cancer activity of ARQ 197, a highly selective oral c-Met Inhibitor, in multiple xenograft models Y Li, D Chen, W Zhou, W Li, J Sun, E Hyatt, Z Jiang, S Makhija, ... Cancer Research 67 (9_Supplement), 2216-2216, 2007 | 11 | 2007 |
| Stat3 pathway inhibitors and cancer stem cell inhibitors Z Jiang, CJ Li, W Li, D Leggett US Patent 9,834,532, 2017 | 10 | 2017 |
